medRxiv

medRxiv
Title	medRxiv
Discipline	Medicine
Abbreviation	medRxiv
Publisher	Cold Spring Harbor Laboratory; Yale University; BMJ
Country	United States
History	2019–present

medRxiv is an open-access online repository for health sciences preprints, launched to accelerate dissemination of clinical and translational research. It operates as a platform for authors to deposit manuscripts prior to formal peer-reviewed publication, enabling rapid visibility among clinicians, researchers, and policymakers. The service interfaces with institutional actors and scholarly journals to balance rapid sharing with safeguards against harm and misinterpretation.

History

medRxiv was announced in 2019 by stakeholders including Cold Spring Harbor Laboratory, Yale University, and BMJ as a counterpart to bioRxiv to serve the medical community. The launch occurred against a backdrop of debates involving World Health Organization, National Institutes of Health, and the Wellcome Trust about preprint policy and rapid data sharing during public-health emergencies. Early governance drew on advisory input from figures with ties to Harvard Medical School, Stanford University School of Medicine, and University of Oxford. The platform’s growth accelerated during the COVID-19 pandemic when high-profile manuscripts from researchers affiliated with institutions such as Imperial College London, Johns Hopkins University, Kaiser Permanente, and University College London appeared, prompting discussion across outlets including The Lancet, New England Journal of Medicine, Nature, and Science. MedRxiv’s model and policies were influenced by precedents set by repositories like arXiv and bioRxiv and by initiatives from organizations such as Center for Open Science, European Commission, and Gates Foundation.

Scope and Content

medRxiv hosts preprints covering clinical trials, public-health studies, epidemiology, health policy, and translational research from contributors at institutions like Mayo Clinic, Massachusetts General Hospital, Mount Sinai Health System, and Cleveland Clinic. Typical subject areas include infectious diseases researched at centers such as Centers for Disease Control and Prevention, oncology studies from groups at MD Anderson Cancer Center, and cardiovascular research connected to American Heart Association investigators. The repository accepts submissions from investigators affiliated with academic units including University of California, San Francisco, Yale School of Medicine, University of Toronto, and international hospitals like Karolinska University Hospital and Singapore General Hospital. Content ranges from case reports and systematic reviews to randomized controlled trials, observational studies, and methodological papers developed at labs such as Broad Institute and clinical networks like National Cancer Institute. medRxiv explicitly excludes certain categories of content associated with ethical or safety concerns, a policy shaped by guidance from Food and Drug Administration and National Health Service stakeholders.

Submission and Screening Process

Authors submit manuscripts through an online portal and designate affiliations such as King's College London, University of Melbourne, or Peking University. Submissions undergo a screening workflow involving checks for plagiarism, competing interests, ethical approval, and potential public-health risk; screening personnel consult standards promoted by Committee on Publication Ethics, International Committee of Medical Journal Editors, and institutional review boards at places like Stanford Hospital. The screening may triage manuscripts relating to emergent events—for example, studies tied to Zika virus or Ebola virus outbreaks—prompting expedited or enhanced review. Although screening is not peer review, medRxiv applies subject-category assignment (e.g., cardiology, psychiatry) and triage decisions that influence visibility and classification alongside metadata linked to repositories such as ClinicalTrials.gov and datasets hosted by entities like Dryad or Figshare.

Access, Licensing, and Copyright

medRxiv provides free access to deposited preprints and supports licensing options commonly used by authors, including Creative Commons licences favored by proponents like OpenAIRE and Creative Commons. Authors retain copyright and often select licences permitting reuse with attribution, aligning with policies advocated by funders such as Wellcome Trust, National Science Foundation, and Gordon and Betty Moore Foundation. The platform enables versioning so updated manuscripts from research groups at institutions such as University of Edinburgh or University of Washington remain discoverable. medRxiv’s terms coordinate with journal policies from publishers including Elsevier, Springer Nature, and Wiley to minimize conflicts when authors later submit to subscription or open-access journals including PLOS Medicine or BMJ Open.

Impact and Reception

medRxiv has influenced scholarly communication by reducing time-to-publicity for clinical findings, a trend observed across citation analyses that reference output from centers like Johns Hopkins Bloomberg School of Public Health and London School of Hygiene & Tropical Medicine. Its role during the COVID-19 pandemic intensified scrutiny: some preprints informed policy deliberations at European Centre for Disease Prevention and Control and national health agencies, while other manuscripts attracted critique from journals such as The BMJ and commentators at Retraction Watch. Supporters cite benefits recognized by researchers at Imperial College London and funders including Chan Zuckerberg Initiative; critics raise concerns echoed by ethicists from Hastings Center and editors at Nature Medicine about unvetted clinical claims and media amplification. Studies comparing preprints with later peer-reviewed articles, involving teams from University of Oxford and University of Cambridge, examined changes in effect sizes, conclusions, and reporting quality.

Relationship with Peer Review and Journals

medRxiv operates complementary to traditional peer review: authors can post preprints prior to or during submission to journals such as The Lancet, New England Journal of Medicine, JAMA, and specialty outlets like Circulation or Gastroenterology. Some journals accept submissions that were previously posted on medRxiv, and editorial policies at publishers including BMJ and Wiley-Blackwell explicitly address preprint disclosure. Peer-review outcomes at journals including Annals of Internal Medicine and JAMA Network Open sometimes lead to multiple revised versions on the repository, while editorial commentary and retractions in outlets like Science and Nature Communications underscore the interplay between preprint visibility and formal scholarly validation. medRxiv thus functions as an interim communication channel interfacing with peer reviewers, editors, and research institutions such as National Institutes of Health and Academic Medical Centers.

Category:Preprint servers